Ocugen, Inc.
NASDAQ:OCGN
0.96 (USD) • At close October 29, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Ocugen, Inc. |
Symbool | OCGN |
Munteenheid | USD |
Prijs | 0.963 |
Beurswaarde | 277,293,611 |
Dividendpercentage | 0% |
52-weken bereik | 0.351 - 2.105 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Shankar Musunuri M.B.A., MBA, Ph.D. |
Website | https://www.ocugen.com |
An error occurred while fetching data.
Over Ocugen, Inc.
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis;
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)